stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Free cash flow
Krystal Biotech, Inc.'s free cash flow for fiscal 2025 was $189.3M, up 58.9% from $119.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $310.1M. Over the past ten years it has ranged from −$153.5M (fiscal 2022) to $189.3M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. Krystal Biotech, Inc. ranks 15th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $189.3M | 58.87% |
| FY2024 | $119.2M | — |
| FY2023 | −$603.0K | — |
| FY2022 | −$153.5M | — |
| FY2021 | −$116.3M | — |
| FY2020 | −$40.9M | — |
| FY2019 | −$25.1M | — |
| FY2018 | −$11.7M | — |
| FY2017 | −$4.1M | — |
| FY2016 | −$1.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $90.3M | 26.72% |
| Jun 2026 | $71.2M | (2.74%) |
| Mar 2026 | $73.2M | (2.83%) |
| Dec 2025 | $75.4M | 98.57% |
| 37 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. | $310.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $130.6M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.4M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$168.7M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$288.1M |
| CYTK Cytokinetics, Incorporated compare | −$588.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement